Tai chi was found to provide clinically important improvements in symptoms and quality of life for patients with fibromyalgia compared to a control group. Patients who practiced tai chi had greater reductions in fibromyalgia impact scores and improvements in physical and mental quality of life components compared to the control group based on standardized assessment scores. The improvements were maintained at 24 weeks follow-up with no adverse events observed.

1. 立足台灣 放眼世界-中醫藥之前景與挑戰
Taiwan and The World-- Prospects and Challenges
of Chinese Medicine
衛生福利部 中醫藥司
Department of Chinese Medicine & Pharmacy
Yi-Tsau Huang (黃 怡 超), M.D., Ph.D.

2. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
衛生福利部
Ministry of Health and Welfare
中醫藥司
Department of
Chinese Medicine
and Pharmacy
國家中醫藥研所
National Research
Institute of Chinese
Medicine
食品藥物
管理署
FDA
…… ……
2

3. Chinese medicine outpatient service
covered by Taiwan’s NHI (1995 onwards)
4

4. Less Birth and Aging Society
0
5
10
15
20
25
1990 2010
2018 2025
2061
15-64
65+
14&under
ageing (25y) super-aged
2000 2021 2031 2041 2051
1993
estimate
aged (7y)
12%
74%
14%
20%
12%
41%
50%
9%
68%
7%
68%
25%
14%
73%
13%
actual
2014
Million
Population Projection in Taiwan ---
5

5. 6
中醫藥發展法
Chinese Medicine and Pharmacy
Development Act

6. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
制定中醫藥發展法
Chinese Medicine and Pharmacy Development Act
7
中醫藥發展法於108年12月31日總統公布實施
Chinese Medicine and Pharmacy Development Act promulgated by
the President on December 31, 2019.

7. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
立法依據及緣由
Legislative Basis and Cause
因應世界衛生組織（WHO）揭櫫「2014-2023年傳統醫學戰略」，
呼籲各國應重視並制定管理傳統醫藥之法律政策。
The World Health Organization’s (WHO) Traditional Medicine Strategy 2014-2023 calls for
nations to place emphasis on traditional medicine and develop management legislatures, as
well as construct a robust regulations system and promote traditional medicine’s contribution
to health for all.
落實我國憲法增修條文第10條第5項所賦予國家應促進現代和傳
統醫藥之研究發展之義務。
Paragraph 5 of Article 10 of the Additional Articles of the Constitution of the R.O.C. (Taiwan)
also stipulated that: “The State shall promote universal health insurance and promote the
research and development of both modern and traditional medicines.”
確立國家中醫藥發展之基本原則。
The principal foundation for the nation’s TCM development
7

8. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
立法願景及目標
Legislative vision and objective
8
促進中醫藥發展
增進全民健康
Promote TCM development&
Improve Taiwan’s health care
永續
政策發展
完善
中醫照護
強化
中藥產業
促進
研究發展
精進
人才培育
目標
願景Vision
目標
Objective
Strengthen
Nurturing Talents
Facilitate Research
Development
Policy on Sustainable
Development
Improvement of
TCM Health Care
Strengthen the
industrialization of TCM

9. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
立法架構 Legislative Framework
章節
Chapter
章節名稱 Name 規範內容Content
1 總則General rovision 立法目的、主管機關、定義及保障經費。
2
中醫藥發展計畫
Plan for TCM development
提升中醫藥管理體系，擬定中長程計畫，設置中醫藥發展諮
議會，整合中醫藥產官學界資源，獎勵或補助中醫藥發展、
中藥製劑之創新與開發及中藥藥用植物種植。
3
中醫醫療及照護
TCM service and health care
增進中醫利用可近性，發展中西醫合作及具中醫特色之醫療
照護，強化中醫藥於全民健康保險與醫療照護體系之功能與
角色。
4
中藥品質管理及
產業發展
Management of TCM quality
and industry development
積極發展中藥藥用植物種植產業，完善從源頭至上市後中藥
管理及風險措施。鼓勵中藥新藥研究與開發，輔導產業開拓
國際市場，提升中藥產業經濟。
5
中醫藥研究發展
TCM Research and
development
推廣及輔導保存具中醫藥特色之知識及傳統技藝，鼓勵中醫
藥產官學合作，進行臨床研究合作，建置國家中醫藥知識庫，
提升實證基礎並加強國際交流，促進中醫藥創新及研究發展。
6
中醫藥人才培育
Nurturing TCM Talents
完善中醫醫事人力規劃，培育中醫藥科技研究人才，普及國
民中醫藥知識，促使中醫藥素養向下扎根。
7
附則
Supplementary Provision
施行日期。
9
Chinese Medicine and Pharmacy Development consistent of 7 Chapters and 24
articles
中醫藥發展法共七章二十五條

10. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
中醫藥發展法子法規推動進度
 為推動中醫藥發展相關獎勵或補助事項，依該法第7條第2
項規定，訂定促進中醫藥研究及發展、中藥製劑創新及開
發、中藥藥用植物種植等事項之獎勵或補助辦法，本部於
109年6月10日預告「中醫藥發展獎勵或補助辦法」草案，
已於8月15日完成預告作業。
 為監測上市中藥品質，確保民眾用藥安全，依該法第14條
規定，本部於109年6月2日預告「上市中藥監測辦法」草
案，已於8月3日完成預告作業。
 為獎勵種植中藥藥用植物，依該法第12條第3項規定，本
部刻研訂「獎勵承租公有土地或國營事業土地種植中藥藥
用植物之承租人及其租賃土地期限保障辦法」草案，並召
開跨部會議研商中。
10

11. 11
Prelude:
Global Trends

12. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
12
List of top level categories
CHAPTER 01 Certain infectious or parasitic diseases
CHAPTER 02 Neoplasms
CHAPTER 03 Diseases of the blood or blood-forming organs
CHAPTER 04 Diseases of the immune system
CHAPTER 05 Endocrine, nutritional or metabolic diseases
CHAPTER 06 Mental, behavioural or neurodevelopmental disorders
CHAPTER 07 Sleep-wake disorders
CHAPTER 08 Diseases of the nervous system
CHAPTER 09 Diseases of the visual system
CHAPTER 10 Diseases of the ear or mastoid process
CHAPTER 11 Diseases of the circulatory system
CHAPTER 12 Diseases of the respiratory system
CHAPTER 13 Diseases of the digestive system
CHAPTER 14 Diseases of the skin
CHAPTER 15 Diseases of the musculoskeletal system or connective tissue
CHAPTER 16 Diseases of the genitourinary system
CHAPTER 17 Conditions related to sexual health
CHAPTER 18 Pregnancy, childbirth or the puerperium
CHAPTER 19 Certain conditions originating in the perinatal period
CHAPTER 20 Developmental anomalies
CHAPTER 21 Symptoms, signs or clinical findings, not elsewhere classified
CHAPTER 22 Injury, poisoning or certain other consequences of external causes
CHAPTER 23 External causes of morbidity or mortality
CHAPTER 24 Factors influencing health status or contact with health services
CHAPTER 25 Codes for special purposes
CHAPTER 26 Supplementary Chapter Traditional Medicine Conditions - Module I

13. Characterization of rheumatoid arthritis subtypes using symptom profiles,
clinical chemistry and metabolomics measurements
Wietmarschen HA van; Dai W, Kooij AJ van der, et al.
PLoS ONE 2012; 7(9): e44331.
14

14. Characterization of rheumatoid arthritis subtypes using symptom profiles,
clinical chemistry and metabolomics measurements
Wietmarschen HA van; Dai W, Kooij AJ van der, et al.
PLoS ONE 2012; 7(9): e44331.
15

15. Frequency and pattern of Chinese herbal medicine
prescriptions for chronic hepatitis in Taiwan
Chen FP, Kung YY, Chen YC, Jong MS, Chen TJ,
Chen FJ, Hwang SJ.
J. Ethnopharmacol. 2008;117:84-91.
Saliva miltiorrhiza (丹參) and Long-dan-xie-
gan-tang (龍膽瀉肝湯) were the most
frequently prescribed single herb (SH) and
herbal formula (HF), respectively.
16

16. Osher Center for Integrative Medicine,
Harvard Medical School
Dr. David Eisenberg
17

17. 2015
18

18. Jan van der
Greef,
Professor of
Analytical
Biosciences at
Leiden University
2015
19

19. 19
20

22. 屠呦呦 教授
21

23. 23Hsu E.: Reflections on the ‘discovery’ of the antimalarial qinghao.
Br. J. Clin. Pharmacol. 2006;61:666-70. 22

24. 青蒿素 (Artemisinin)
Artemisinin is extracted from the leaves of
Artermesia annua.
"瘧疾寒熱"
"用青蒿一握，水二升，擣汁服之。“
”以水二升漬，絞取汁，盡服之 ”
晉 葛洪《肘後備急方》治寒热諸瘧方第十六
( A.D. 284－363年.)
23

25. 25White NJ.: Qinghaosu (Artemisinin):The price of success. Science 2008;320:330-4.
24

26. 屠呦呦 教授
25

27. Tu YY (屠呦呦 教授): Nat. Med. 2011;17:xix-xxii 26

28. Tu YY (屠呦呦 教授): Nat. Med. 2011;17:xix-xxii 27

29. A Randomized Trial of Tai Chi for Fibromyalgia
Wang C, Schmid CH, Rones R, Kalish R, Yinh J,
Goldenberg DL, M.D., Lee Y, McAlindon T.
N. Engl. J. Med. 2010; 363: 743-54.
Dr. Chenchen Wang
王琛琛 醫師

30. From: Wang C et al. N. Engl. J. Med. 2010; 363: 743-54.
Of the 66 randomly assigned patients, the 33 in the tai chi
group had clinically important improvements in the FIQ total
score and quality of life. Mean (±SD) baseline and 12-week FIQ
scores for the tai chi group were 62.9±15.5 and 35.1±18.8,
respectively, versus 68.0±11 and 58.6±17.6, respectively, for the
control group (change from baseline in the tai chi group vs.
change from baseline in the control group, −18.4 points;
P<0.001). The corresponding SF-36 physical-component scores
were 28.5±8.4 and 37.0±10.5 for the tai chi group versus
28.0±7.8 and 29.4±7.4 for the control group (between-group
difference, 7.1 points; P=0.001), and the mental-component
scores were 42.6±12.2 and 50.3±10.2 for the tai chi group versus
37.8±10.5 and 39.4±11.9 for the control group (between-group
difference, 6.1 points; P=0.03). Improvements were maintained
at 24 weeks (between-group difference in the FIQ score, −18.3
points; P<0.001). No adverse events were observed.

32. From: Wang C et al. N. Engl. J. Med. 2010; 363: 743-54.

33. From: Wang C et al. N. Engl. J. Med. 2010; 363: 743-54.

34. Effect of tai chi versus aerobic exercise for
fibromyalgia: comparative effectiveness
randomized controlled trial
Wang C, Schmid CH, Rones R, Kalish R, Yinh J,
Goldenberg DL, M.D., Lee Y, McAlindon T.
BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k851
Dr. Chenchen Wang
王琛琛 醫師

36. Tai Chi and Postural Stability in Patients
with Parkinson's Disease
Li F., Harmer P., Fitzgerald K., Eckstrom E., Stock R.,
Galver J., Maddalozzo G. and Batya S.S.
N. Engl. J. Med. 2012; 366: 511-9.
李福忠 (Fuzhong Li ) 博士

37. From: Li F et al. N. Engl. J. Med. 2012; 366: 511-9.
195 patients with Parkinson's disease assigned one of three
groups: tai chi, resistance training, or stretching. The patients
participated in 60-minute exercise sessions twice weekly for 24
weeks. The primary outcomes were changes from baseline in
the limits-of-stability test (maximum excursion and directional
control; range, 0 to 100%). Secondary outcomes included
measures of gait and strength, scores on functional-reach and
timed up-and-go tests, motor scores on the Unified Parkinson's
Disease Rating Scale, and number of falls. The tai chi group
performed consistently better than the resistance-training and
stretching groups in maximum excursion and in directional
control. The tai chi group also performed better than the
stretching group in all secondary outcomes and outperformed
the resistance-training group in stride length and functional
reach. Tai chi lowered the incidence of falls as compared with
stretching but not as compared with resistance training.

38. 38
From: Li F et al. N. Engl. J. Med. 2012; 366: 511-9.

39. 39
From: Li F et al. N. Engl. J. Med. 2012; 366: 511-9.

40. 40
From: Li F et al. N. Engl. J. Med. 2012; 366: 511-9.

41. Non-aristolochic acid prescribed Chinese
herbal medicines and the risk of mortality in
patients with chronic kidney disease: results
from a population-based follow-up study
Hsieh CF, Huang SL, Chen CL, Chen WT,
Chang HC, Wu ML, Yang CC.
BMJ Open 2014;4:e004033
28

42. Hsieh CF et al.: BMJ Open 2014;4:e004033. 29

43. Association of prescribed Chinese herbal
medicine use with risk of end-stage renal disease
in patients with chronic kidney disease
Lin M-Y, Chiu Y-W, Chang J-S, Lin H-L,
Lee CT-C, Chiu G-F, Kuo M-C, Wu M-T,
Chen H-C and Hwang S-J
Kidney Int. 2015; 88: 1365–1373
30

44. Lin MY et al.: Kidney Int. 2015 Aug 5. doi: 10.1038/ki.2015.226.
31

45. Lin MY et al.: Kidney Int. 2015 Aug 5. doi: 10.1038/ki.2015.226.
32

46. A Retrospective Cohort Study Comparing Stroke
Recurrence Rate in Ischemic Stroke Patients With
and Without Acupuncture Treatment
Shih CC, Liao CC, Sun MF, Su YC, Wen CP,
Morisky DE, Sung FC, Hsu CY, Lin JG.
Medicine 2015 Sep;94 (39):e1572.
doi:10.1097/MD.0000000000001572.
33

47. Shih CC et al.: Medicine 2015 Sep;94 (39):e1572.
Recurrence-free probability

48. Shih CC et al.: Medicine 2015 Sep;94 (39):e1572. 34

49. 49
未來展望與挑戰
Future Prospects and Challenges

50. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
促進中醫發展
Promote the Development of CM
滾動檢討中醫醫療機構負責醫師訓練制度，並持續辦理中醫醫院評鑑，
以確保中醫醫療品質。
Rolling review of Chinese medicine medical institutions responsible for physician training
system, and continue to apply for evaluation of Chinese medicine hospitals to ensure the
quality of Chinese medicine.
推動中醫臨床技能評估模式及中醫專科醫師訓練制度，建立客觀評估標
準並培育具實證科學研發與教學能力之中醫師。
Promote the Chinese medicine clinical skills assessment model and Chinese medicine
physicians training system. To establish objective evaluation criteria and cultivate physicians
with empirical scientific R&D and teaching capabilities.
建立多元中西醫合作照護模式，並發展中醫特色健康照顧服務。
Strengthen the training and counseling of Traditional Medical personnel, and recruit new
Traditional Medical support personnel to improve the TCM medical and nursing team.
推動中醫優質發展計畫(2020-2025年)，行政院2019年5月3日核定。
Proposed a project for Chinese Medicine development (2020-2025).
The Executive Yuan approved on May 3, 2019.
50

51. 衛生福利部
Ministry of Health and Welfare
Ministry of Health and Welfare
提升中藥品質管理
Improve TCM Quality
滾動式檢討中藥材含異常物質限量(二氧化硫、重金屬、黃麴毒素及農藥)
Rolling review of TCM materials abnormal substances (sulfur dioxide, heavy
metals, aflatoxins, and pesticide residue)
推動中藥廠確效作業，中藥濃縮製劑自2020年1月1日起分階段實施。
Promote the establish validation capability of TCM factories. The operational
benchmarks of validation among concentrated TCM pharmaceutical factories
will be implement in phases from 2020.
增訂濃縮製劑指標成分含量測定規範及分析方法開發，精進中藥製劑品質。
Research and development of the determination of the content of the indicator
components of concentrated preparations and the development of analytical
methods to improve the quality of TCM preparations.
持續編修臺灣中藥典，2021年出版臺灣中藥典第四版。
Taiwan Herbal Pharmacopeia (THP) 4th edition will be updated in 2021.
51

52. Thanks for your attention!
52